15.82
-0.10
(-0.63%)
Real-time:
2:07PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 15.70 - 15.99 |
| 52 week | 13.15 - 18.00 |
| Open | 15.81 |
| Vol / Avg. | 24,390.00/67,141.00 |
| Mkt cap | 331.86M |
| P/E | - |
| Div/yield | - |
| EPS | -1.98 |
| Shares | 20.98M |
| Beta | 1.91 |
| Inst. own | 81% |
Events
Jul 26, 2013
Q2 2013 Safeguard Scientifics Inc. Earnings Release
Jul 9, 2013
Safeguard Scientifics Inc. at MedCity CONVERGE
- 10:00AM EDT -
May 23, 2013
Safeguard Scientifics Inc. Annual Shareholder Meeting
May 20, 2013
Safeguard Scientifics Inc. at B. Riley & Co. Investor Conference
Apr 25, 2013
Q1 2013 Safeguard Scientifics Inc. Earnings Conference Call
Apr 22, 2013
Q1 2013 Safeguard Scientifics Inc. Earnings Release
Apr 10, 2013
Safeguard Scientifics Inc. at 3 Rivers Venture Fair
Apr 6, 2013
Safeguard Scientifics Inc. at Notre Dame University CARE "Impact of Emerging Information Technology on Capital Markets" Conference
Mar 13, 2013
Safeguard Scientifics Inc. at Southeast Venture Conference
Mar 13, 2013
Safeguard Scientifics Inc. at Saul Ewing LLP Medical Device Roundtable
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -13.02% | -10.08% |
| Return on average equity | -15.54% | -11.89% |
| Employees | 31 | - |
| Carbon Disclosure Rating | - | - |
Address
Building 800, 435 Devon Park Drive
WAYNE, PA 19087-1945
United States - Map
+1-610-2930600 (Phone)
+1-610-2930601 (Fax)
WAYNE, PA 19087-1945
United States - Map
+1-610-2930600 (Phone)
+1-610-2930601 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Safeguard Scientifics, Inc. provides growth capital for entrepreneurial and innovative life sciences and technology companies. The Firm targets life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine, Specialty Pharmaceuticals and selected healthcare services; and technology companies in Internet / New Media, Financial Services IT, Healthcare IT and selected business services with capital requirements of up to $25 million. The Firm participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings.
Officers and directors
| Andrew E. Lietz | Independent Chairman of the Board | |
| Stephen T. Zarrilli | President, Chief Executive Officer, Director | |
| Jeffrey B. McGroarty CPA | Chief Financial Officer, Senior Vice President - Finance | |
| Timothy J. Levy | Corporate Counsel | |
| James A. Datin | Executive Vice President, Managing Director | |
| Brian J. Sisko | Executive Vice President, Managing Director | |
| Steven J. Grenfell CPA | Vice President - Operations | |
| Mark A. Mitchell | Principal | |
| Jim P. O'Connell | Principal | |
| Gary J. Kurtzman M.D. | Managing Director |